A Public Health Approach to the Prevention of Inhibitors in Hemophilia

Soucie, J. Michael; Miller, Connie H.; Kelly, Fiona M.; Oakley, Meredith; Brown, Deborah L.; Kucab, Phillip

doi:10.1016/j.amepre.2014.07.007

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

A Public Health Approach to the Prevention of Inhibitors in Hemophilia

11 2014
By Soucie, J. Michael ; Miller, Connie H. ; Kelly, Fiona M. ; ...
http://dx.doi.org/10.1016/j.amepre.2014.07.007
Source: Am J Prev Med. 47(5):669-673

[PDF-70.61 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Am J Prev Med
Personal Author:

Soucie, J. Michael ; Miller, Connie H. ; Kelly, Fiona M. ; Oakley, Meredith ; Brown, Deborah L. ; ... More +

Soucie, J. Michael ; Miller, Connie H. ; Kelly, Fiona M. ; Oakley, Meredith ; Brown, Deborah L. ; Kucab, Phillip Less -
Description:

The development of an antibody in people with hemophilia to products used in the treatment and prevention of bleeding, also referred to as an inhibitor, is the most serious complication of hemophilia care today. CDC, together with healthcare providers, consumer organizations, hemophilia organizations, and federal partners, has developed a public health agenda to prevent the development of inhibitors. This paper describes a public health approach that combines a national surveillance program with epidemiologic, laboratory, and prevention research to address knowledge gaps in rates and risk factors for inhibitor development, and in knowledge and behaviors of patients and providers, in addition to screening and treatment practices.
Subjects:

[+]

Community Networks Hemophilia A Humans Population Surveillance Public Health Risk Factors United States
Source:

Am J Prev Med. 47(5):669-673
Pubmed ID:

25245801
Pubmed Central ID:

PMC4469363
Document Type:

Journal Article
Funding:

CC999999/Intramural CDC HHSUnited States/
Volume:

47
Issue:

5
Collection(s):

CDC Public Access
Main Document Checksum:

[+]

urn:sha256:4bf3e0034d389bbf9c261297489c8e1cc5723ac16210cd4f27b0c1f2a13b3eee
Download URL:

https://stacks.cdc.gov/view/cdc/31656/cdc_31656_DS1.pdf
File Type:

nihms699357.nxml

xml

More +